KRAS and adenocarcinoma: KRAS mutations were more frequent in the null immunophenotype (>40%), whereas EGFR mutations predominated in adenocarcinoma phenotypes.[8,9] Most LCLC cases were reclassified as adenocarcinomas or squamous carcinomas after immunohistochemical subtyping, with rare residual null or indeterminate immunophenotypes.